The UK’s National Institute for Health and Care Excellence is supporting  the coverage of UCB’s Cimzia and Novartis’ Cosentyx for use either alone or in combination with methotrexate to treat psoriatic arthritis.

Both can be used with methotrexate, if the person has had a TNF-alpha inhibitor but the disease has stopped responding after the first 12 weeks, and if the drug is provided through a patient access scheme.